RxDoctor Payments Data

Evan Jacobs, MD

Cardiovascular Disease · Coconut Creek, FLNPI 1215179882

Payments from drug & device makers

$5,592in general payments, 2019–2025

Across 166 payments — averaging $33.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Abbott$1K
  • Novartis$710
  • Johnson & Johnson$412
  • Boehringer Ingelheim$328
  • Boston Scientific$222
  • plus $1K from 12 others

What the payments were for

  • Food & beverage$5,580100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,592 in reported general payments places this provider in the 60th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$3,924
Medicare patients
17
Services billed
38

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban107$141,017
XareltoRivaroxaban50$64,456
EntrestoSacubitril/Valsartan18$26,421
JardianceEmpagliflozin15$22,150
Repatha SureclickEvolocumab27$16,606
Metoprolol Succinate198$3,045
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide88$1,772
Valsartan56$1,713
Atorvastatin Calcium128$1,089
Dilt-XrDiltiazem Hcl19$796
Carvedilol109$680
ClopidogrelClopidogrel Bisulfate62$625
Nifedipine ErNifedipine19$617
Rosuvastatin Calcium73$580
Ranolazine ErRanolazine11$578

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$112$141,017107 claims
Johnson & JohnsonXarelto$412$64,45650 claims
NovartisEntresto$710$26,42118 claims
Boehringer IngelheimJardiance$328$22,15015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Coconut Creek

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →